

Int. Appln. No.: PCT/US04/024052
US Appln. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 15

RECEIVED
CENTRAL FAX CENTER

MAY 21 2007

REMARKS

The Office Action dated November 15, 2006, has been carefully considered. The Applicants respectfully request reconsideration of the application in view of the following remarks.

Claims 1-32 are pending.

Claims 1-32 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-25 of US Patent No. 7,101,871.

The Applicants concurrently submit a Terminal Disclaimer under 37 CFR 1.321(b) to obviate the obviousness-type patenting rejection. The Applicants therein have disclaimed the terminal part of any patent issuing from the present application which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 7,101,871. The terminal disclaimer fully complies with 37 CFR 3.73(b). Accordingly, the double patenting rejection should be withdrawn.

Information Disclosure Statement

A supplemental Information Disclosure Statement was filed on December 12, 2006, to comply with 37 CFR 1.98(a)(2).

Int. Appl. No.: PCT/US04/024052
US Appl. No.: 10/566,235
US Filing Date: Jan. 27, 2006
Case No.: 21482YP
Page No.: 16

In view of the foregoing, it is respectfully requested that the Examiner allow the application to pass to issue.

Respectfully submitted,

By 

Philippe L. Durette
Reg. No. 35,125
Attorney for Applicants
Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-4568

Date: January 11, 2007